Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a ...

Recent Exact Sciences Corporation financials show accelerating revenue growth and stable margins, despite ongoing investments in screening and MRD. While EXAS maintains leadership in stool-based CRC ...

Exact Sciences has launched its long-awaited blood test designed to detect the early stages of multiple tumors, with a plan to sell it to consumers through a telehealth program in a bid to increase ...

Welcome to our weekly Search Engine Land series, Everything you need to know about Google Ads in less than 3 minutes. Every Wednesday, I’m highlighting a different Google Ads feature, and what you ...